Clinical implications of loss of RUNX3 and/or SMAD4 expression in the tumor epithelial compartment may be used to identify stage II patients in need of adjuvant chemotherapy, or patients with T1-3N1 tumors eligible for extended chemotherapy compared to the three month standard for this risk group. Here, SMAD4 is linked to neoplasm.